NICE recommends vedolizumab for adults with moderately to severely active Crohn’s Disease (CD) who have either failed, were intolerant or contraindicated to an anti-TNF
NICE has published final draft guidance on vedolizumab for the treatment of adult patients with moderately to severely active CD who have either failed, or were intolerant or contraindicated to an anti-TNF
SMC accepts Entyvio for restricted use within NHS Scotland for the treatment of adult patients with moderately to severely active CD who have had an inadequate response with, lost response to or were intolerant to an anti-TNF
Final NICE guidance published on Entyvio® (vedolizumab), the first gut-selective treatment for ulcerative colitis (UC)
Landmark decision by SMC gives Scottish patients access to Entyvio® (vedolizumab), the first gut-selective treatment for ulcerative colitis
World’s first gut-selective treatment for ulcerative colitis made available to UK patients
The National Institute for Health and Care Excellence (NICE) has recommended Entyvio for adults with moderately to severely active ulcerative colitis (UC) across its full licenced indication
Entyvio® (vedolizumab) becomes first biologic treatment to receive provisional yes from NICE for maintenance therapy in ulcerative colitis, a condition that affects over 140,000 Britons
First and only gut-selective treatment for Ulcerative Colitis and Crohn’s Disease provides new option for people failing on existing treatments
New humanised monoclonal antibody vedolizumab (Entyvio®) becomes the first gut-selective treatment licensed for moderately to severely active Ulcerative Colitis and Crohn’s Disease
Takeda Receives European Commission Marketing Authorisation for Entyvio® (vedolizumab) for the Treatment of Ulcerative Colitis and Crohn’s Disease
Takeda's New Investigational Drug Vedolizumab Entered Phase 3 Clinical Trials in Japan For the Treatment of Ulcerative Colitis and Crohn's Disease
FDA Advisory Committee Recommends Approval of Takeda’s Investigational Biologic Vedolizumab
If you have been prescribed Entyvio and get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not listed within this website or in the Patient Information Leaflet.
Adverse events should be reported. In the United Kingdom, reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Takeda on 01628 537900 or e-mail DSO-UK@takeda.com